Jazz’s reworked narcolepsy drug wins 7 years of orphan exclusivity thanks to rare ‘clinical superiority’ finding from FDA

Jazz Pharmaceuticals successfully redesigned its blockbuster narcolepsy drug Xyrem to make it safer by greatly reducing its sodium content. That tweak was enough for Jazz to win 7 years of orphan drug exclusivity for that redesigned followup — marketed as Xywav — as part of an infrequently used FDA program...

Click to view original post